Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Vitamin D supplementation does not improve semen quality in infertile men

12 Mar 2018
The difference of expectations of infertility treatments between a man and a woman can create difficulty for couples to know when they should stop trying.

There is no improvement in semen quality among vitamin D-insufficient infertile men taking high-dose vitamin D supplementation, a recent study has found.

Men in the treatment group had significantly higher serum 25-hydroxyvitamin-D (25OHD) levels and 1,25-dihydroxyvitamin D3 than those in the placebo group.

No association existed between vitamin D supplementation and changes in semen parameters, but spontaneous pregnancies tended to be higher in couples in which the man was in the treatment group (7.3 percent vs 2.4 percent; Δ5.0 percent (–0.6 to 10.5 percent).

A subgroup of oligozoospermic men receiving vitamin D treatment had a higher likelihood for a live birth compared with those on placebo (35.6 percent vs 18.3 percent; Δ17.3 percent; 1.6–32.9 percent). In addition, vitamin D-deficient men who were randomized to receive high-dose vitamin D supplementation had higher serum inhibin B levels (193 vs 143 pg/mL; Δ49 pg/mL; 8–91 pg/mL). However, increase in sperm concentration was not significantly higher than in the placebo group (p=0.07).

“The positive impact of vitamin D supplementation on live birth rate and serum inhibin B in oligozoospermic and vitamin D–deficient men may be of clinical importance and warrant verification by others,” the authors said.

In this single-centre, triple-blinded, randomized clinical trial, 1,427 infertile men were screened to include 330. A total of 1,007 men were excluded, while 95 declined to participate. The active group received cholecalciferol 300,000 IU initially, then 1,400 IU cholecalciferol and 500 mg of calcium daily for 150 days. The other group was given placebo.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.